COMparative Performance of General Purpose Models

NCT ID: NCT06584097

Last Updated: 2024-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-02

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the performance of the Eleveld models for propofol and remifentanil on neurosurgery patients admitted to intensive care with their intraoperative performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite the widespread adoption of Target Controlled Infusion (TCI) models in modern clinical anesthesia practice, much less attention has been paid in the literature to their potential applications in the Intensive Care Unit (ICU) setting. Few studies have been published so far to evaluate the performance of TCI pumps for sedatives and other drugs (e.g., antibiotics) in Intensive Care. Further data is needed regarding the use of TCI for the long-term infusion of these drugs in the ICU after surgery, and the quantitative relationship between generalized pharmacokinetic/pharmacodynamic models for propofol and remifentanil (the Eleveld models) has yet to be evaluated in this specific population. This study is an observational study with the aim of clarifying the predictive performance of the TCI models for the administration of propofol and remifentanil in a cohort of intensive care patients admitted after neurosurgery and compare it to the intraoperative performance, which can be taken as benchmark.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurosurgical Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients undergoing elective neurosurgical procedures with an expected sedation after surgery of \> 12 hours • Requirement for an arterial line

Exclusion Criteria

* Pregnancy

* Known sensitivity or allergy to propofol or remifentanil
* Patient participating in research for which a period of exclusion is currently required by other study protocol, ethical committee or health authority.
* Age \< 18 years old
* Patients subjected to infusion of propofol and/or remifentanil not delivered through TCI pumps before the inclusion
* Patients exposed to other sedatives (benzodiazepines, volatile anesthetics, quetiapine) before the inclusion
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Groningen

OTHER

Sponsor Role collaborator

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michele Introna, M.d.

Role: PRINCIPAL_INVESTIGATOR

Fondazione IRCCS Istituto Neurologico C. Besta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Foundation IRCCS Carlo Besta Neurological Institute

Milan, Italy, Italy

Site Status RECRUITING

Fondazione IRCCS Istituto Neurologico C. Besta

Milan, Milano, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michele Introna, M.D.

Role: CONTACT

00390223942420

Marco Gemma, M.D.

Role: CONTACT

0039022394.2411

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michele Introna, M.D.

Role: primary

0223942420

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COMPARE ICU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.